Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | XBP1 | P17861 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080560 | 0.91 | NAMPT (0.64) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13055402 | 0.90 | CYP17A1 (0.59) | SMN1; SMN2L3MBTL1CYP17A1ALDH1A1PSMB8 | |
| SCHEMBL22548863 | 0.88 | CYP17A1 (0.57) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL15996891 | 0.87 | SMN1; SMN2 (0.53) | MEN1KMT2ARAB9AMAPTSMN1; SMN2 | |
| SCHEMBL22548789 | 0.85 | CYP17A1 (0.51) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL23619661 | 0.85 | SMN1; SMN2 (0.62) | NPC1RAB9AMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL20865536 | 0.85 | CYP17A1 (0.68) | SMN1; SMN2HTTL3MBTL1CYP17A1PSMB8 | |
| SCHEMBL22804523 | 0.84 | CA12 (0.47) | NPC1RAB9AMAPTSMN1; SMN2CYP17A1 | |
| SCHEMBL29811040 | 0.84 | CA12 (0.47) | NPC1RAB9AMAPTSMN1; SMN2CYP17A1 | |
| SCHEMBL15996917 | 0.83 | NPC1 (0.53) | NPC1RAB9AMAPTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054616-A1 | PLATFORM APPROACH F-18 RADIOLABELING OF VARIOUS PEPTIDES IN AQUEOUS MEDIUM | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-118666725-A | Compound with antibacterial activity, preparation method thereof and antibacterial agent | 西华大学 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-117800975-A | Compounds with anti-KRAS mutant tumor activity | 泰励生物科技（上海）有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-116867779-A | KRAS inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-116096710-A | 4-oxo-3, 4-dihydroquinazolinone compounds for the treatment of BRAF related diseases and disorders | 阿雷生物药品公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20220289720-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | UNIVERSITY OF HAWAII | 2022-09-15 | — | — | US | disclosed |
| CN-115043788-A | Trifluoromethyl oxazole-2-ketone compound and preparation method and application thereof | 南京工业大学 | 2022-09-13 | — | — | CN | disclosed |
| CN-114920738-A | KRas inhibitors for cancer treatment | 泰励生物科技（上海）有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20040248887-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-12-09 | — | — | US | disclosed |
| WO-2004084843-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
| CN-1426405-A | Novel cyclic amide derivative | MITSUBISHI PHARMACEUTICALS INC (JP) | 2003-06-25 | — | — | CN | disclosed |
| WO-1996016980-A1 | MORPHOLINOETHYLAMIDE DERIVATIVES | NOVARTIS AG (CH) | 1996-06-06 | — | — | WO | disclosed |
| EP-0065864-B1 | ANTI-HYPERTENSIVE 1-SUBSTITUTED SPIRO (PIPERIDINE-OXOBENZOXAZINES) | SYNTEX (U.S.A.) INC. (US) | 1985-08-28 | — | — | EP | disclosed |
| EP-0065864-A1 | Anti-hypertensive 1-substituted spiro (piperidine-oxobenzoxazines) | SYNTEX (U.S.A.) INC. (US) | 1982-12-01 | — | — | EP | disclosed |
| US-4349549-A | Anti-hypertensive 1-substituted spiro(piperidine-oxobenzoxazine)s | SYNTEX (U.S.A.) INC. (US) | 1982-09-14 | — | — | US | disclosed |
| EP-0030845-A2 | Pharmacologically active peptides, their preparation and pharmaceutical compositions containing them | ELI LILLY AND COMPANY (US) | 1981-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248887-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | MEN1 3815/4885KMT2A 4282/4885NPC1 82/4885 |
| US-20220289720-A1 | ARYL SULFONAMIDES AS SMALL MOLECULE STAT3 INHIBITORS | STAT3, JAK2, STAT6 | MEN1 4749/4885KMT2A 611/4885NPC1 1883/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | MEN1 4426/4885KMT2A 1526/4885NPC1 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.